Lineage Cell Therapeutics, Inc. LCTX 34.6
Health Care · NYSE · Data as of 2026-05-12
Lineage Cell Therapeutics, Inc. (LCTX) has delivered +15.1% annualized revenue growth, n/a earnings growth, and n/a dividend growth over 10 years of data. Ranked #1717 of 1993 stocks overall and #221 of 264 in the Health Care sector by Steady Score.
Industry
Biological Products
Steady Score
34.6
Overall Rank
#1717 / 1993
Sector Rank
#221 / 264
Revenue CAGR
+15.1%
Earnings CAGR
-
Dividend CAGR
-
?
E/R CAGR Ratio
-
Revenue
Earnings
Dividends
Free Cash Flow
Margin
NET Margin
FCF Margin
Payout Ratio
Payout Ratio
FCF Payout Ratio